These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9109909)

  • 1. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults?
    Hämäläinen ML; Hoppu K; Santavuori P
    Neurology; 1997 Apr; 48(4):1100-3. PubMed ID: 9109909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
    Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
    Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
    Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
    Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
    Winner P; Rothner AD; Wooten JD; Webster C; Ames M
    Headache; 2006 Feb; 46(2):212-22. PubMed ID: 16492230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
    Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study.
    Fujita M; Sato K; Nishioka H; Sakai F
    Cephalalgia; 2014 Apr; 34(5):365-75. PubMed ID: 24163282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.
    Goadsby PJ; Ferrari MD; Olesen J; Stovner LJ; Senard JM; Jackson NC; Poole PH
    Neurology; 2000 Jan; 54(1):156-63. PubMed ID: 10636142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
    Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
    Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents.
    Winner P; Rothner AD; Saper J; Nett R; Asgharnejad M; Laurenza A; Austin R; Peykamian M
    Pediatrics; 2000 Nov; 106(5):989-97. PubMed ID: 11061765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.
    Tepper SJ; Cady R; Dodick D; Freitag FG; Hutchinson SL; Twomey C; Kuhn TA
    Headache; 2006 Jan; 46(1):115-24. PubMed ID: 16412159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults.
    Wendt J; Cady R; Singer R; Peters K; Webster C; Kori S; Byrd S
    Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies.
    Winner P; Mannix LK; Putnam DG; McNeal S; Kwong J; O'Quinn S; Richardson MS
    Mayo Clin Proc; 2003 Oct; 78(10):1214-22. PubMed ID: 14531480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial.
    Ahonen K; Hämäläinen ML; Rantala H; Hoppu K
    Neurology; 2004 Mar; 62(6):883-7. PubMed ID: 15037686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
    Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
    Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study.
    Lipton RB; McGinley JS; Shulman KJ; Wirth RJ; Buse DC
    Headache; 2017 Nov; 57(10):1570-1582. PubMed ID: 28880380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral sumatriptan for the long-term treatment of migraine: clinical findings.
    Rederich G; Rapoport A; Cutler N; Hazelrigg R; Jamerson B
    Neurology; 1995 Aug; 45(8 Suppl 7):S15-20. PubMed ID: 7644080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study.
    Lipton RB; Stewart WF; Cady R; Hall C; O'Quinn S; Kuhn T; Gutterman D
    Headache; 2000; 40(10):783-91. PubMed ID: 11135021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
    Rao AS; Gelaye B; Kurth T; Dash PD; Nitchie H; Peterlin BL
    Headache; 2016 Feb; 56(2):331-40. PubMed ID: 26840902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
    Diener HC
    Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal sumatriptan for the acute treatment of migraine in children.
    Ueberall MA; Wenzel D
    Neurology; 1999 Apr; 52(7):1507-10. PubMed ID: 10227648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.